Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

339 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The future of antiretroviral therapy: challenges and needs.
Moreno S, López Aldeguer J, Arribas JR, Domingo P, Iribarren JA, Ribera E, Rivero A, Pulido F; HIV 2020 Project. Moreno S, et al. Among authors: pulido f. J Antimicrob Chemother. 2010 May;65(5):827-35. doi: 10.1093/jac/dkq061. Epub 2010 Mar 12. J Antimicrob Chemother. 2010. PMID: 20228080 Review.
High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients).
Arribas JR, Pulido F, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Del Palacio A, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group. Arribas JR, et al. Among authors: pulido f. AIDS. 2002 Jul 26;16(11):1554-6. doi: 10.1097/00002030-200207260-00014. AIDS. 2002. PMID: 12131195 Clinical Trial.
Underpowered clinical trials of antiretroviral treatment.
Arribas JR, Pulido F. Arribas JR, et al. Among authors: pulido f. JAMA. 2002 Nov 6;288(17):2120; author reply 2120-1. doi: 10.1001/jama.288.17.2120. JAMA. 2002. PMID: 12413367 No abstract available.
Treatment of advanced HIV infection.
Pulido F, Arribas JR. Pulido F, et al. J Antimicrob Chemother. 2003 Feb;51(2):225-7. doi: 10.1093/jac/dkg065. J Antimicrob Chemother. 2003. PMID: 12562685 Review. No abstract available.
Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction].
Berenguer J, Laguna F, López-Aldeguer J, Moreno S, Arribas JR, Arrizabalaga J, Baraia J, Casado JL, Cosín J, Polo R, González-García J, Iribarren JA, Kindelán JM, López-Bernaldo de Quirós JC, López-Vélez R, Lorenzo JF, Lozano F, Mallolas J, Miró JM, Pulido F, Ribera E. Berenguer J, et al. Among authors: pulido f. Enferm Infecc Microbiol Clin. 2004 Mar;22(3):160-76. doi: 10.1016/s0213-005x(04)73057-8. Enferm Infecc Microbiol Clin. 2004. PMID: 14987537 Review. English, Spanish.
Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).
Pulido F, Arribas JR, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Cepeda C, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group. Pulido F, et al. J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):343-50. doi: 10.1097/00126334-200404010-00003. J Acquir Immune Defic Syndr. 2004. PMID: 15097150
Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C, Dronda F, Antela A, Sanz J, Navas E, Miralles P, Berenguer J, Pérez S, Zapata A, González-García JJ, Peña JM, Vázquez JJ, Arribas JR. Montes ML, et al. Among authors: pulido f. J Antimicrob Chemother. 2005 May;55(5):800-4. doi: 10.1093/jac/dki063. Epub 2005 Mar 10. J Antimicrob Chemother. 2005. PMID: 15761071 Clinical Trial.
Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).
Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, Arranz A, González-García JJ, Cepeda C, Hervás R, Paño JR, Gaya F, Carcas A, Montes ML, Costa JR, Peña JM. Arribas JR, et al. Among authors: pulido f. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):280-7. doi: 10.1097/01.qai.0000180077.59159.f4. J Acquir Immune Defic Syndr. 2005. PMID: 16249701 Clinical Trial.
[Antiretroviral treatment in patient with advanced immunosuppression].
Arribas JR, Pulido F, González-García JJ, Miró JM. Arribas JR, et al. Among authors: pulido f. Med Clin (Barc). 2006 Feb 4;126(4):157-8; author reply 158-9. doi: 10.1157/13084025. Med Clin (Barc). 2006. PMID: 16472503 Spanish. No abstract available.
[Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection].
Polo R, José Galindo M, Martínez E, Alvarez J, Arévalo JM, Asensi V, Cánoves D, Cáncer E, Collazos J, Estrada V, Gómez-Candela C, Johnston S, Locutura J, López-Aldeguer J, Lozano F, Miralles C, Muñoz-Sanz A, Ortega E, Pascua J, Pedrol E, Pulido F, San Martín M, Sanz J, Viciana P, Chamorro L; Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS). Polo R, et al. Among authors: pulido f. Enferm Infecc Microbiol Clin. 2006 Feb;24(2):96-117. doi: 10.1157/13085017. Enferm Infecc Microbiol Clin. 2006. PMID: 16545318 Spanish.
339 results